Abstract
The efficacy of antibiotherapy of infectious diseases is strongly compromised by the advent and spread of antibiotic resistance. Active efflux of cytotoxic drugs mediated by multi-drug transporters is the basis of multi-drug resistance in prokaryotic cells. Thus, inhibition of efflux pumps appears to be a promising strategy to combat multi-drug resistance pathogens. Different classes of inhibitors structurally unrelated have been patented in the last decade.